Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Up 307.9% in March

Dermata Therapeutics, Inc. (NASDAQ:DRMA) was the target of a large growth in short interest in March. As of March 31st, there was short interest totalling 770,100 shares, a growth of 307.9% from the March 15th total of 188,800 shares. Approximately 19.3% of the company’s stock are short sold. Based on an average trading volume of 1,560,000 shares, the short-interest ratio is currently 0.5 days.

Dermata Therapeutics Stock Down 8.8 %

Dermata Therapeutics stock traded down $0.07 during mid-day trading on Wednesday, hitting $0.71. The company had a trading volume of 113,186 shares, compared to its average volume of 1,152,041. The business has a fifty day moving average of $1.11 and a 200 day moving average of $1.23. Dermata Therapeutics has a 1 year low of $0.70 and a 1 year high of $6.17. The stock has a market cap of $3.86 million, a price-to-earnings ratio of -0.04 and a beta of 0.58.

About Dermata Therapeutics

Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.